Can I read Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial on EtoBox?

Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial by Ling‐Long Tang MD1 | Lin Chen MD1 | Gui‐Qiong Xu MD2 | Ning Zhang MD3 is a book available to read on EtoBox.

What is Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial about?

Abstractand Fang‐Yun Xie, Department of RadiationBackground: Nearly 90% locoregionally advanced nasopharyngeal carcinomaOncology, State Key Laboratory of Oncology(LANPC) responds to induction chemotherapy (IC) with significant tumor volumein South China, Guangdong Key Laboratory ofNasopharyngeal Carcinoma Diagnosis andshrinkage. Radiotherapy always follows IC, and reduced volume has been proposed.Therapy, Guangdong Provincial ClinicalHowever, the efficacy and safety of reduced‐volume radiotherapy is uncertain.Research Center for Cancer, Sun Yat‐senUniversity Cancer Center, No. 651 Road DongMethods: In this multi‐center, noninferiority, randomized, controlled trial, patientsFeng East, Guangzhou, Guangdong, China.with LANPC who completed IC were randomly assigned (1:1) to receive reduced‐Email: [email protected];[email protected]; [email protected];volume radiotherapy based on post‐IC tumor volume (Post‐IC group) or [email protected] and [email protected] radiotherapy based on pre‐IC tumor volume (Pre‐IC group). The primaryFunding informationendpoint was locoregional relapse‐free survival, with a noninferiority margin of 8%.Noncommunicable Chronic

Author

Ling‐Long Tang MD1 | Lin Chen MD1 | Gui‐Qiong Xu MD2 | Ning Zhang MD3

Published

2025

Language

EN